![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
DISCOVER in Europe: a Subanalysis of the Phase 3, Randomized, Controlled Trial of Daily Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-exposure Prophylaxis
|
|
|
17th European AIDS Conference (EACS), 6-9 November 2019, Basel, Switzerland
Reported by Jules Levin
Frank Post,1 Christoph Spinner,2 Pep Coll,3 Trevor Hawkins,4 Jonathon Anderson,4 Lijie Zhong,4 Scott McCallister4
1King's College Hospital, London, UK; 2Klinikum rechts der Isar, Technische Universität München Fakultät für Medizin, München, Germany; 3BCN Checkpoint, IrsiCaixa AIDS Institut de Recerca de la Sida, Barcelona, Spain; 4Gilead Sciences, Inc., Foster City, California, USA
![1112191](../images/111219/111219-16/1112191.gif)
![1112192](../images/111219/111219-16/1112192.gif)
![1112193](../images/111219/111219-16/1112193.gif)
![1112194](../images/111219/111219-16/1112194.gif)
![1112195](../images/111219/111219-16/1112195.gif)
![1112196](../images/111219/111219-16/1112196.gif)
![1112197](../images/111219/111219-16/1112197.gif)
References: 1. Descovy [package insert]. Foster City, CA: Gilead Sciences, Inc.: 10/2019; 2. Hare CB, et al. CROI 2019. abstr 104; 3. Hayes R, et al. Euro Surveillance. 2019 Oct;24.
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|